ArmaGen taps Big Pharma interest in 'Trojan horse' tech to get drugs into brain

ArmaGen Technologies closed a $17 million Series A venture funding round with contributions from three global pharmaceutical companies and a Japanese investor for the Los Angeles-based company's platform technology designed to get both small and large molecule drugs across the blood-brain barrier (BBB).